Disappointment for Australian pharma as govt snubs stability deal
This article was originally published in SRA
Executive Summary
Medicines Australia has expressed its disappointment at the decision by the country's health minister not to sign a strategic agreement that would have provided the Australian R&D-based pharmaceutical industry with some policy stability over the next five years in return for it agreeing to support medicines access and sustainability measures including price cuts to medicines listed on the Pharmaceutical Benefits Scheme.